Sickle Cell Disease Care Management and Treatment Continuing Education

Summary

The bill mandates that any health‑care practitioner registered with the DEA and authorized to prescribe controlled substances must finish a board‑approved two‑hour continuing‑education course. The training covers current prescribing standards, alternatives, non‑drug therapies, emergency opioid antagonists, addiction risks, and pain treatment for sickle‑cell disease. It aims to improve safe prescribing and pain care while tying completion to license renewal.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share